BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, May 3, 2026
Home » Authors » Elise Mak

Elise Mak

Articles

ARTICLES

Hong Kong PolyU collaborates with European institutions on R&D platform

March 19, 2018
By Elise Mak
HONG KONG – Hong Kong Polytechnic University (PolyU) is partnering with two European institutions to establish a life sciences and engineering R&D platform to spearhead applied research.
Read More

JW Therapeutics draws $90M, new investors in series A round for CAR T candidate

March 13, 2018
By Elise Mak

HONG KONG – JW Therapeutics (Shanghai) Co. Ltd. raised $90 million in a series A financing for the development of its first CD19-directed investigational cancer therapy, JWCAR-029. Investors include prominent names such as Singapore-based Temasek, Sequoia Capital China and Yuanming Capital.


Read More

Multinational companies see opportunity as IVD market set to triple in China

March 12, 2018
By Elise Mak

JW Therapeutics draws $90M, new investors in series A round for CAR T candidate

March 12, 2018
By Elise Mak
HONG KONG – JW Therapeutics (Shanghai) Co. Ltd. raised $90 million in a series A financing for the development of its first CD19-directed investigational cancer therapy, JWCAR-029. Investors include prominent names such as Singapore-based Temasek, Sequoia Capital China and Yuanming Capital.
Read More

Golden Meditech licensed for genetic testing in China

March 9, 2018
By Elise Mak

Trial recruitment easier in China? Not so fast, according to analysis

March 6, 2018
By Elise Mak

HONG KONG – The sheer speed of growth of the biotech and med-tech industries in China has easily outpaced the development of regulation and has led to concerns that too many of the ballooning number of clinical trials in the country fail to meet enrollment targets.


Read More

Trial recruitment easier in China? Not so fast, according to analysis

March 1, 2018
By Elise Mak

Trial recruitment easier in China? Not so fast, according to analysis

March 1, 2018
By Elise Mak
HONG KONG – The sheer speed of growth of the biotech and med-tech industries in China has easily outpaced the development of regulation and has led to concerns that too many of the ballooning number of clinical trials in the country fail to meet enrollment targets.
Read More

Pre-revenue biotech startups go public in Hong Kong under new listing rules

Feb. 28, 2018
By Elise Mak
HONG KONG – Biotech companies that have not yet generated any revenue can seek listing on the Main Board of the Hong Kong Stock Exchange (HKEX). The exchange proposed the new policy Friday as part of the effort to lure more firms to go public, bolstering Hong Kong's biotech development.
Read More

Pre-revenue biotech startups get green light to go public in Hong Kong

Feb. 27, 2018
By Elise Mak
View All Articles by Elise Mak

Popular Stories

  • AI generated image for researcher developing antisense oligonucleotides

    Bio Korea 2026 kicks off with spotlight on oligonucleotides

    BioWorld
    Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
  • Chinabio 2026 partnering

    Chinese biotechs gain leverage as partners in dealmaking

    BioWorld
    China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
  • University of Western Australia patents 5-HT2A/B modulators

    BioWorld Science
    University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
  • Neurons

    AA meeting of minds as PTC, Novartis push votoplam in HD

    BioWorld
    What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
  • Nerves within a melanoma tumor

    Innervation can slow, as well as speed, tumor growth, study finds

    BioWorld
    Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing